Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Carcinoma, Hepatocellular 9Neoplasms 7Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Recurrence 4Prostatic Neoplasms 4Melanoma 4Breast Neoplasms 4Lymphoma, B-Cell, Marginal Zone 3Lymphoma 3Head and Neck Neoplasms 3Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Polycystic Ovary Syndrome 2Pleural Effusion, Malignant 2Mesothelioma, Malignant 2Leukemia, Lymphocytic, Chronic, B-Cell 2Anxiety Disorders 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Rare Malignant Neoplasm 1Pancreatic Neoplasms 1Neuroblastoma 1Nephrotic Syndrome 1Neoplasms, Plasma Cell 1NSCLC 1Myeloproliferative Disorders 1Multiple Myeloma 1

Interventions

Doxorubicin 142Ifosfamide 85Radiotherapy 82Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 40Etoposide 39Docetaxel 39Vincristine 37Trabectedin 37Cisplatin 35Nivolumab 32Magnetic Resonance Spectroscopy 26Irinotecan 26Carboplatin 25Temozolomide 23Surgical Procedures, Operative 23Radiation 22Ipilimumab 22Bevacizumab 20Blood Specimen Collection 19Granulocyte Colony-Stimulating Factor 18Biopsy 18eribulin 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma × Pharmaceutical Preparations × Clear all
NCT04138381 2023-03-27

SeliGIST

Grupo Espanol de Investigacion en Sarcomas

Phase 1/2 Unknown
30 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Drug-Related Side Effects and Adverse Reactions

NCT03698227 2020-07-15

OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Terminated
2 enrolled
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡